Alector, Inc. (ALEC) is reported to have a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert, which together may be deemed to beneficially own 9,374,267 shares of Alector common stock as of September 18, 2026. This represents approximately 8.4% of the 111,656,919 shares outstanding as of July 31, 2026. The stake is held across several affiliated funds, including Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS LP, with investment and voting authority allocated among related general partners and management entities. The reporting persons include various Delaware and Cayman Islands entities and Mark N. Lampert, who signs as authorized signatory for the group and disclaims beneficial ownership beyond the interests attributed through these entities.
Positive
None.
Negative
None.
Key Figures
Total beneficially owned shares:9,374,267 sharesBeneficial ownership percentage:8.4%Biotechnology Value Fund, L.P. holdings:4,900,143 shares+4 more
7 metrics
Total beneficially owned shares9,374,267 sharesShares of Alector common stock that BVF-related entities and Mark N. Lampert may be deemed to own as of September 18, 2026
Beneficial ownership percentage8.4%Percentage of Alector common stock that BVF-related entities and Mark N. Lampert may be deemed to beneficially own, based on 111,656,919 shares outstanding
Biotechnology Value Fund, L.P. holdings4,900,143 sharesAlector common shares beneficially owned by Biotechnology Value Fund, L.P. as of September 18, 2026 (about 4.4% of the class)
Biotechnology Value Fund II, L.P. holdings3,671,016 sharesAlector common shares beneficially owned by Biotechnology Value Fund II, L.P. as of September 18, 2026 (about 3.3% of the class)
Trading Fund OS LP holdings619,317 sharesAlector common shares beneficially owned by Biotechnology Value Trading Fund OS LP as of September 18, 2026 (less than 1% of the class)
Shares outstanding111,656,919 sharesAlector common shares outstanding as of July 31, 2026, used to calculate ownership percentages
BVF GP Holdings LLC aggregate stake8,571,159 sharesShares beneficially owned in the aggregate by Biotechnology Value Fund, L.P. and Biotechnology Value Fund II, L.P. that BVF GP Holdings LLC may be deemed to own
"As of the close of business on September 18, 2026, (i) BVF beneficially owned 4,900,143 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 9,374,267.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
dispositive powerfinancial
"Shared Dispositive Power 9,374,267.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
Schedule 13Gregulatory
"Item 8. | Identification and Classification of Members of the Group."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
investment managerfinancial
"Partners, as the investment manager of BVF, BVF2 and Trading Fund OS"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Alector (ALEC) does the Biotechnology Value Fund group report owning?
The Biotechnology Value Fund group and Mark N. Lampert may be deemed to beneficially own 8.4% of Alector’s outstanding common stock, representing 9,374,267 shares as of September 18, 2026.
How many Alector (ALEC) shares does each main BVF fund hold?
As of September 18, 2026, Biotechnology Value Fund, L.P. holds 4,900,143 shares, Biotechnology Value Fund II, L.P. holds 3,671,016 shares, and Biotechnology Value Trading Fund OS LP holds 619,317 shares of Alector common stock.
What is the total number of Alector (ALEC) shares outstanding used to calculate BVF’s ownership?
The ownership percentages are based on 111,656,919 Alector common shares outstanding as of July 31, 2026, as reported in Alector’s Quarterly Report on Form 10-Q filed on August 6, 2026.
Who are the reporting persons in this Schedule 13G for Alector (ALEC)?
Reporting persons include Biotechnology Value Fund, L.P., related BVF and Trading Fund entities, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively referred to as the “Reporting Persons.”
Does Mark N. Lampert directly own Alector (ALEC) shares in this report?
Mark N. Lampert may be deemed to beneficially own 9,374,267 shares through his role as a director and officer of BVF Inc., but he and other reporting persons expressly disclaim beneficial ownership of shares owned by the various BVF entities.
What voting power does the BVF group report over Alector (ALEC) shares?
The BVF entities report shared voting and dispositive power over their Alector shares, with no sole voting or dispositive power. BVF Partners L.P., BVF Inc., and Mark N. Lampert share voting and dispositive power over the aggregated 9,374,267 shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Alector, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
014442107
(CUSIP Number)
09/11/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND L P
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,900,143.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,900,143.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,900,143.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.4 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BVF I GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,900,143.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,900,143.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,900,143.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.4 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND II LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,671,016.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,671,016.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,671,016.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BVF II GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,671,016.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,671,016.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,671,016.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
Biotechnology Value Trading Fund OS LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
619,317.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
619,317.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
619,317.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BVF Partners OS Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
619,317.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
619,317.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
619,317.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BVF GP HOLDINGS LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
8,571,159.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
8,571,159.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
8,571,159.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BVF PARTNERS L P/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,374,267.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,374,267.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,374,267.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.4 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
BVF INC/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,374,267.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,374,267.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,374,267.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.4 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
014442107
1
Names of Reporting Persons
LAMPERT MARK N
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,374,267.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,374,267.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,374,267.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.4 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Alector, Inc.
(b)
Address of issuer's principal executive offices:
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA 94080
Item 2.
(a)
Name of person filing:
Biotechnology Value Fund, L.P. ("BVF")
BVF I GP LLC ("BVF GP")
Biotechnology Value Fund II, L.P. ("BVF2")
BVF II GP LLC ("BVF2 GP")
Biotechnology Value Trading Fund OS LP ("Trading Fund OS")
BVF Partners OS Ltd. ("Partners OS")
BVF GP Holdings LLC ("BVF GPH")
BVF Partners L.P. ("Partners")
BVF Inc.
Mark N. Lampert ("Mr. Lampert")
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
Biotechnology Value Fund, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF I GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Fund II, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF II GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Trading Fund OS LP
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF Partners OS Ltd.
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF GP Holdings LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Partners L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Mark N. Lampert
44 Montgomery St., 40th Floor
San Francisco, California 94104
(c)
Citizenship:
Biotechnology Value Fund, L.P.
Delaware
BVF I GP LLC
Delaware
Biotechnology Value Fund II, L.P.
Delaware
BVF II GP LLC
Delaware
Biotechnology Value Trading Fund OS LP
Cayman Islands
BVF Partners OS Ltd.
Cayman Islands
BVF GP Holdings LLC
Delaware
BVF Partners L.P.
Delaware
BVF Inc.
Delaware
Mark N. Lampert
United States
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
014442107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on September 18, 2026, (i) BVF beneficially owned 4,900,143 shares of the Issuer's Common Stock, $0.0001 par value per share (the "Shares"), (ii) BVF2 beneficially owned 3,671,016 Shares and (iii) Trading Fund OS beneficially owned 619,317 Shares.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,900,143 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,671,016 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 619,317 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 8,571,159 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 9,374,267 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 183,791 Shares held in the Partners Managed Account.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 9,374,267 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 9,374,267 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)
Percent of class:
The following percentages are based on 111,656,919 Shares outstanding as of July 31, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026.
As of the close of business on September 18, 2026, (i) BVF beneficially owned approximately 4.4% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.3% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 4.4% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.3% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 7.7% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 8.4% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF and BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
BIOTECHNOLOGY VALUE FUND L P
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BVF I GP LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BVF II GP LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
Biotechnology Value Trading Fund OS LP
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BVF Partners OS Ltd.
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BVF GP HOLDINGS LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BVF PARTNERS L P/IL
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
BVF INC/IL
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/18/2026
LAMPERT MARK N
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert
Date:
09/18/2026
Exhibit Information
99.1 - Joint Filing Agreement, September 18, 2026.
